Stock listing

Ose Immunotherapeutics Sa

Selected listing: ORPOF · OTC · USD · US

Ose Immunotherapeutics Sa (OTC:ORPOF), Health Technology. Latest release Sep 28, 2026: OSE Immunotherapeutics Reports its Cash Position as of June 30, 2026…

ORPOF:OTCUSDUSUpdated October 3, 2026

Ticker: OTC:ORPOF
Asset type: Stock
Sector: Health Technology
Industry: Pharmaceuticals: Major
Exchange: OTC
Currency: USD

Latest news from Ose Immunotherapeutics Sa

OSE Immunotherapeutics Reports its Cash Position as of June 30, 2026, and Provides Business Update

September 28, 2026

OSE Immunotherapeutics Announces Presentation of Combi-TED Phase 2 Topline Results of Tedopi® in Non-Small Cell Lung Cancer at the ESMO 2026 Meeting

September 23, 2026

OSE Immunotherapeutics annonce la présentation des principaux résultats de l'étude de Phase 2 Combi-TED de Tedopi® dans le cancer du poumon non à petites cellules au Congrès 2026 de l’ESMO

September 22, 2026

OSE Immunotherapeutics Welcomes First Patient Dosed by Veloxis in the Phase 2 RENGEVITY-201 Trial Evaluating Pegrizeprument (VEL-101) for the Prevention of Organ Rejection in Kidney Transplant Recipients

September 9, 2026

OSE Immunotherapeutics se félicite de l’inclusion du premier patient traité par Veloxis dans l’étude de phase 2 RENGEVITY-201 évaluant le pegrizeprument (VEL-101) dans la prévention du rejet d’organe chez les patients transplantés rénaux

September 8, 2026

All Ose Immunotherapeutics Sa news →

Research Ose Immunotherapeutics Sa

Ose Immunotherapeutics Sa company profile

View the public company page for Ose Immunotherapeutics Sa on 6ix.

Ose Immunotherapeutics Sa news

Read company news and market updates connected to Ose Immunotherapeutics Sa.

Ose Immunotherapeutics Sa investor events

Find investor webinars, events, and replay context for Ose Immunotherapeutics Sa.